GnRH Agonist at Embryo Transfer: IVF Outcomes

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Infertility, Infertility, Female, Infertility, Male

In brief

In ART (assisted reproductive technology) cycles, embryos are transferred to a woman's uterus after in-vitro fertilization (IVF) in a laboratory. Usually, hormones (progesterone) are given to the patient after transferring the embryo, as a supplement, in order to mimic the natural hormones that would normally be secreted in an unassisted pregnancy. This study will identify whether additional gonadotropin-releasing hormone (GnRH-agonist) administration, a natural hormone secreted from the hypothalamus, will improve the clinical pregnancy and live birth rates when using IVF.

Key facts

Study ID

NCT03544073

Run by

Maimonides Medical Center

People needed

0

Starts

2019-04-15

Expected to finish

2021-06-30

Last updated by the study team

2019-04-16

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women undergoing in-vitro fertilization who are receiving an embryo transfer of a day 5 blastocyst

You may not qualify if…

• Those who have a contraindication to receiving the medication

Where it is running

• Genesis Fertility Center — Brooklyn, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.